SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...

Health experts are alarmed as Republicans degrade the country’s pivotal HIV programs — and break promises made during Trump’s ...

The disclosure by director of Women’s Health at the Ministry of Health Dr Adesh Sirjusingh that syphilis infections among pregnant women are on the rise in Trinidad and Tobago is ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

Either we get ahead of this crisis or watch a generation of Americans be swept into the devastating grip of disease.

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

WHO emphasizes integrating surveillance into national STI programs. Zoliflodacin, a novel antimicrobial agent, shows promise in treating gonorrhea, demonstrating non-inferiority to ...

Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).